People with allergic fungal rhinosinusitis taking Dupixent (dupilumab) saw significant improvement in congestion and sinus ...

Most people are familiar with bacterial sinus infections that come with seasonal colds or allergies, but another, potentially more serious type of infection often goes unrecognized until it causes ...

The approval makes Dupixent the first FDA-approved therapy for allergic fungal rhinosinusitis, supported by Phase III data showing significant improvements in sinus opacification, nasal symptoms, and ...

Phase 3 LIBERTY-AIMS results showed dupilumab reduced nasal polyp size and sinus symptoms in adults and children with allergic fungal rhinosinusitis.

The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older.

Dupixent (dupilumab) is now FDA-approved for adults and children aged 6 years and older with allergic fungal rhinosinusitis and prior sino-nasal surgery.

Sinus aspergillosis is a fungal infection that affects the sinuses. People with weakened immune systems and respiratory conditions are more likely to develop this condition. Aspergillus is a mold that ...

JAMA used a case report of rhino-orbital-cerebral mucormycosis in a patient with uncontrolled diabetes to demonstrate correct and incorrect treatment choices. A recent case report highlights ...

Medically reviewed by Brigid Dwyer, MD Key Takeaways When a headache begins, take brief notes about possible triggers (e.g., stress, diet, weather changes, and other activities).Treat your sinus ...

The FDA approved Dupixent as the first treatment for allergic fungal rhinosinusitis in adults and children over six years old ...